Taylor Piontek
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,687 of the $53,794 with a category attached, or 60.8%. Gilead accounts for 88.7% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $29,644, more than ten times the $1,048 reported in 2021. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 393 payments — averaging $136.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$48K
- Viiv Healthcare Company$4K
- Johnson & Johnson$503
- Merck$318
- Janssen Products, LP$199
- Theratechnologies Inc.$168
- plus $645 from 10 others
What the payments were for
- Consulting fees$32,68761%
- Speaking & faculty fees$8,62816%
- Travel & lodging$1,5373%
- Food & beverage$10,74420%
- Education$1990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 176 | $47,730 |
| Viiv Healthcare Company | 145 | $4,232 |
| Johnson & Johnson | 24 | $503 |
| Merck | 15 | $318 |
| Janssen Products, LP | 2 | $199 |
| Theratechnologies Inc. | 8 | $168 |
| Janssen Scientific Affairs, LLC | 4 | $127 |
| Organon | 3 | $104 |
| Napo Pharmaceuticals Inc | 5 | $86 |
| Hologic Sales And Service, LLC | 1 | $79 |
| GSK | 2 | $65 |
| Alkermes, Inc. | 2 | $55 |
| EMD Serono, Inc. | 2 | $53 |
| AbbVie | 2 | $39 |
| Boston Scientific | 1 | $22 |
| Oxford Immunotec USA Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,794 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 19 | $77,155 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $32,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $47,730 | $109,41832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Tempe
- Sharon MagalonaMesa$441K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Celeste FineGilbert$82K
- Mia ChorneyChandler$79K
- Jennifer PrinceScottsdale$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.